MLKL and melanoma: In line with the recent report, Dabrafenib but not Vemurafenib blocked necroptosis (Figures 6a and b; black bars) and MLKL phosphorylation (Figures 6c and d), but also protected from DL/IAP antagonist-mediated apoptosis (Figures 6a and b; grey bars) in RIPK3-reconstituted A375 or IGR melanoma cells.